VANCOUVER, BC, May 28, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“), a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce the formation of its scientific advisory board (“SAB”). The SAB is comprised of international industry experts and pioneers in the fields of neuropsychopharmacology…


Previous articleThe Psilocybin vs. Escitalopram Trial – Part 1
Next articlePTSF61 – Archetypal Astrology and the Inner Healer, with Renn Butler